MSB 3.21% $1.13 mesoblast limited

Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD, page-86

  1. 5,838 Posts.
    lightbulb Created with Sketch. 2110
    If they require meetings for every bit of submitted data, then I can see why their workload would be overwhelming!
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.